参考文献
[1] Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014,63(12):1123-1133. DOI: 10.1016/j.jacc.2013.11.053.
[2] Farmakis D, Agostoni P, Baholli L, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus[J]. Int J Cardiol, 2019,297:83-90. DOI: 10.1016/j.ijcard.2019.09.005.
[3] 徐毅 , 罗卓卡 , 黄霏霏 , 等 . 正性肌力药物作用靶点的研究进展 [J]. 中国新药杂志 ,2012,21(3):268-272. DOI:CNKI:SUN:ZXYZ.0.2012-03-012.
[4] Agostoni P, Farmakis DT, García-Pinilla JM, et al. Haemodynamic balance in acute and advanced heart failure: an expert perspective on the role of levosimendan[J]. Card Fail Rev, 2019,5(3):155-161. DOI: 10.15420/cfr.2019.01.R1.
[5] Sorsa T, Pollesello P, Rosevear PR, et al. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization[J]. Eur J Pharmacol, 2004,486(1):1-8. DOI: 10.1016/j.ejphar.2003.12.006.
[6] Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan[J]. Int J Cardiol, 2012,159(2):82-87. DOI: 10.1016/j.ijcard.2011.07.022.
[7] Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels[J]. Anesth Analg, 2000,90(1):5-11. DOI: 10.1097/00000539-200001000-00003.
[8] Kopustinskiene DM, Pollesello P, Saris NE. Potassiumspecific effects of levosimendan on heart mitochondria[J]. Biochem Pharmacol, 2004,68(5):807-812. DOI: 10.1016/j.bcp.2004.05.018.
[9] Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan[J]. Br J Clin Pharmacol, 2004,57(4):412-415. DOI: 10.1111/j.1365-2125.2003.02043.x.
[10] Bouchez S, Fedele F, Giannakoulas G, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application[J]. Cardiovasc Drugs Ther, 2018,32(6):617-624. DOI: 10.1007/s10557-018-6838-2.
[11] Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium[J]. Eur J Pharmacol, 2000,400(1):103-112. DOI: 10.1016/s0014-2999(00)00385-x.
[12] Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report[J]. Cardiovasc Drugs Ther, 2013,27(6):581-590. DOI: 10.1007/s10557-013-6485-6.
[13] Branzi G, Malfatto G, Villani A, et al. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure[J]. J Cardiovasc Med (Hagerstown), 2010,11(9):662-668. DOI: 10.2459/JCM.0b013e32833832f6.
[14] De Luca L, Sardella G, Proietti P, et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study[J]. J Am Soc Echocardiogr, 2006,19(2):172-177. DOI: 10.1016/j.echo.2005.08.016.
[15] Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure[J]. Heart, 2006,92(12):1768-1772. DOI: 10.1136/hrt.2006.079707.
[16] Lin YK, Chen YC, Chen YA, et al. Levosimendan differentially modulates electrophysiological activities of sinoatrial nodes, pulmonary veins, and the left and right atria[J]. J Cardiovasc Electrophysiol, 2018,29(8):1150-1158. DOI: 10.1111/jce.13629.
[17] Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake[J]. Circulation, 2005,111(12):1504-1509. DOI: 10.1161/01.CIR.0000159252.82444.22.
[18] Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper[J]. Int J Cardiol, 2016,222:303-312. DOI: 10.1016/j.ijcard.2016.07.202.
[19] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南 2018[J]. 中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cam.j.issn.0253-3758.2018.10.004.
[20] 中国医师协会急诊医师分会 , 中国心胸血管麻醉学会急救与复苏分会 . 中国急性心力衰竭急诊临床实践指南(2017)[J]. 中华急诊医学杂志 ,2017,26(12):1347-1357. DOI: 10.3760/cma.j.issn.1671-0282.2017.12.003.
[21] Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial[J]. Lancet, 2002,360(9328):196-202. DOI: 10.1016/s0140-6736(02)09455-2.
[22] 王雷,崔亮,魏嘉平,等 . 静脉注射左西孟旦治疗重度失代偿性心力衰竭患者的疗效分析 [J]. 中华心血管病杂志,2010,38(6):527-530. DOI: 10.3760/cma.j.issn.0253-3758. 2010.06.011.
[23] 贾志 , 郭牧 , 张丽媛 , 等 . 左西孟旦与米力农治疗心力衰竭的疗效比较 [J]. 中华急诊医学杂志 ,2014,23(7):740-745.DOI:10.3760/cma.j.issn.1671-0282.2014.07.006.
[24] Moiseyev VS, Põder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)[J]. Eur Heart J, 2002,23(18):1422-1432. DOI: 10.1053/euhj.2001.3158.
[25] 李传威 , 孙志军 , 杨波 , 等 . 左西孟旦改善急性心肌梗死伴心力衰竭患者近期血流动力学的研究 [J]. 中华老年多器官疾病杂志 ,2016,15(4):241-244. DOI: 10.11915/j.issn.1671- 5403.2016.04.058.
[26] Jia Z, Guo M, Zhang YQ, et al. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction[J]. Cardiology, 2014,128(2):195-201. DOI: 10.1159/000357864.
[27] 中国医师协会心血管内科医师分会,中国心血管健康联盟,心肌梗死后心力衰竭防治专家共识工作组 . 2020 心肌梗死后心力衰竭防治专家共识 [J]. 中国循环杂志,2020,35(12):1170-1184. DOI:10.3969/j.issn.1000-3614.2020.12.002.
[28] Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial[J]. J Am Heart Assoc, 2018,7(16):e008455. DOI: 10.1161/JAHA.117.008455.
[29] Greco T, Calabrò MG, Covello RD, et al. A Bayesian network meta-analysis on the effect of inodilatory agents on mortality[J]. Br J Anaesth, 2015,114(5):746-756. DOI: 10.1093/bja/aeu446.
[30] Tasal A, Demir M, Kanadasi M, et al. Comparison of singledose and repeated levosimendaninfusion in patients with acute exacerbation of advanced heart failure[J]. Med Sci Monit, 2014,20:276-282. DOI: 10.12659/MSM.889767.
[31] Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial[J]. Eur J Heart Fail, 2014,16(8):898-906. DOI: 10.1002/ejhf.118.
[32] Comín-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial[J]. Eur J Heart Fail, 2018,20(7):1128-1136. DOI: 10.1002/ejhf.1145.
[33] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016,18(8):891-975. DOI: 10.1002/ejhf.592.
[34] Bouchez S, Fedele F, Giannakoulas G, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application[J]. Cardiovasc Drugs Ther, 2018,32(6):617-624. DOI: 10.1007/s10557-018-6838-2.
[35] Chang W, Xie JF, Xu JY, et al. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials[J]. BMJ Open, 2018,8(3):e019338. DOI: 10.1136/bmjopen-2017-019338.
[36] Meng JB, Hu MH, Lai ZZ, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial[J]. Med Sci Monit, 2016,22:1486-1496. DOI: 10.12659/msm.898457.
[37] Tena MÁ, Urso S, González JM, et al. Levosimendan versus placebo in cardiac surgery: a systematic review and metaanalysis[J]. Interact Cardiovasc Thorac Surg, 2018,27(5):677-685. DOI: 10.1093/icvts/ivy133.
[38] Jacky A, Rudiger A, Krüger B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery-A retrospective before-and-after study[J]. J Cardiothorac Vasc Anesth, 2018,32(5):2112-2119. DOI: 10.1053/j.jvca.2018.04.019.
[39] Pirracchio R, Parenica J, Resche Rigon M, et al. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis[J]. PLoS One,2013,8(8):e71659. DOI: 10.1371/journal.pone.0071659.
[40] Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure[J]. Heart, 2006,92(12):1768-1772. DOI: 10.1136/hrt.2006.079707.
[41] 国家卫生计生委合理用药专家委员会,中国药师协会 . 心力衰竭合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2019,11(7):1-78. DOI:10.12037/YXQY.2019.07-01.
[42] Nieminen MS, Buerke M, Cohen-Solál A, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion[J]. Int J Cardiol, 2016,218:150-157. DOI: 10.1016/j.ijcard.2016.05.009.
[43] Harjola VP, Giannakoulas G, von Lewinski D, et al. Use of levosimendan in acute heart failure[J]. Eur Heart J Suppl, 2018,20(Suppl I):I2-2I10. DOI: 10.1093/eurheartj/suy039.
[44] Kundra TS, Nagaraja PS, Bharathi KS, et al. Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement[J]. Ann Card Anaesth, 2018,21(3):328-332. DOI: 10.4103/aca.ACA_19_18.
[45] Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?[J]. Curr Opin Crit Care, 2019,25(4):384-390. DOI: 10.1097/MCC.0000000000000632.
[46] Fotbolcu H, Duman D. A promising new inotrope: levosimendan[J]. Anadolu Kardiyol Derg, 2010,10(2):176-182. DOI: 10.5152/akd.2010.045.
[47] Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan[J]. Clin Pharmacokinet, 2007,46(7):535-552. DOI: 10.2165/00003088-200746070-00001.
[48] Papp JG, Pollesello P, Varró AF, et al. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusioninduced arrhythmias in dogs[J]. J Cardiovasc Pharmacol Ther, 2006,11(2):129-135. DOI: 10.1177/1074248406289286.